Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

RESUMO Este artigo apresenta o consenso realizado pelo Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia sobre os critérios diagnósticos da Doença de Alzheimer (DA) no Brasil. Foi realizada uma revisão da literatura e dos critérios clínicos e de pesquisa para DA, sendo propostos protocolos para o diagnóstico de DA em níveis de atenção primária, secundária e terciária. Dentro deste cenário clínico, são apresentados os critérios diagnósticos para DA típica e atípica, além de instrumentos de avaliação clínica, cognitiva e funcional; bem como propedêutica complementar com exames laboratoriais e de neuroimagem. A utilização de biomarcadores é também apresentada, tanto para o diagnóstico clínico em situações específicas quanto para pesquisa.

[1]  P. Scheltens,et al.  Research Criteria for the Behavioral Variant of Alzheimer Disease , 2021, JAMA neurology.

[2]  M. Yassuda,et al.  The Figure Memory Test: diagnosis of memory impairment in populations with heterogeneous educational background , 2021, Dementia & neuropsychologia.

[3]  C. Anderson,et al.  Systematic review of coexistent epileptic seizures and Alzheimer's disease: Incidence and prevalence , 2021, Journal of the American Geriatrics Society.

[4]  David T. Jones,et al.  New insights into atypical Alzheimer's disease in the era of biomarkers , 2021, The Lancet Neurology.

[5]  D. Malta,et al.  Dementias in Brazil: increasing burden in the 2000–2016 period. Estimates from the Global Burden of Disease Study 2016 , 2020, Arquivos de Neuro-Psiquiatria.

[6]  D. Galimberti,et al.  Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease , 2020, NeuroImage: Clinical.

[7]  M. Filippi,et al.  An update on magnetic resonance imaging markers in AD , 2020, Therapeutic advances in neurological disorders.

[8]  J. Cummings,et al.  Repurposed agents in the Alzheimer’s disease drug development pipeline , 2020, Alzheimer's Research & Therapy.

[9]  D. Rujescu,et al.  Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives , 2020, Frontiers in Psychiatry.

[10]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[11]  Peter R. Martin,et al.  Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. , 2020, Brain : a journal of neurology.

[12]  J. Santabárbara,et al.  Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis , 2020, Brain sciences.

[13]  David T. Jones,et al.  Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes , 2020, Brain communications.

[14]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[15]  G. Frisoni,et al.  Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. , 2020, The Cochrane database of systematic reviews.

[16]  H. Matsuda,et al.  Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET , 2019, Japanese Journal of Radiology.

[17]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2019 , 2019, Alzheimer's & dementia.

[18]  A. Sinclair,et al.  Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype , 2019, Alzheimer's & Dementia.

[19]  Yanguo Xin,et al.  Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis , 2019, Neuroscience & Biobehavioral Reviews.

[20]  J. Clarimón,et al.  Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[21]  P. Lewczuk,et al.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease , 2019, Alzheimer's Research & Therapy.

[22]  M. Yassuda,et al.  Screening for Alzheimer's disease in low-educated or illiterate older adults in Brazil: a systematic review , 2018, Arquivos de Neuro-Psiquiatria.

[23]  K. Blennow,et al.  Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report , 2019, The Journal of Prevention of Alzheimer's Disease.

[24]  Jong Hun Kim.  Genetics of Alzheimer's Disease , 2018, Dementia and neurocognitive disorders.

[25]  I. Lacerda,et al.  Patterns of discrepancies in different objects of awareness in mild and moderate Alzheimer’s disease , 2018, Aging & mental health.

[26]  Sterling C. Johnson,et al.  Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia , 2018, Molecular Neurobiology.

[27]  M. Gorno-Tempini,et al.  Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review , 2018, Front. Neurol..

[28]  O. Forlenza,et al.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[29]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[30]  L. Mosconi,et al.  Clinical Application of APOE in Alzheimer’s Prevention: A Precision Medicine Approach , 2018, The Journal of Prevention of Alzheimer's Disease.

[31]  D. Salmon,et al.  Alzheimer’s Disease: Past, Present, and Future , 2017, Journal of the International Neuropsychological Society.

[32]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[33]  K. Blennow.  A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood , 2017, Neurology and Therapy.

[34]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[35]  Nick C. Fox,et al.  Consensus classification of posterior cortical atrophy , 2017, Alzheimer's & Dementia.

[36]  F. Hane,et al.  Recent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology , 2017, Journal of Alzheimer's disease : JAD.

[37]  Irving E. Vega,et al.  Biomarkers for the Early Detection and Progression of Alzheimer’s Disease , 2016, Neurotherapeutics.

[38]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[39]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[40]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[41]  R. Buckner,et al.  Polygenic risk of Alzheimer disease is associated with early- and late-life processes , 2016, Neurology.

[42]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[43]  Hanna Cho,et al.  TAU PET IN ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT , 2016, Alzheimer's & Dementia.

[44]  R. Buckner,et al.  POLYGENIC RISK OF ALZHEIMER’S DISEASE IS ASSOCIATED WITH EARLY AND LATE LIFE PROCESSES , 2016, Alzheimer's & Dementia.

[45]  R. M. Oliveira,et al.  Brazilian Normative Data on Letter and Category Fluency Tasks: Effects of Gender, Age, and Geopolitical Region , 2016, Front. Psychol..

[46]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[47]  S. Gauthier,et al.  Imaging Alzheimer's disease pathophysiology with PET , 2016, Dementia & neuropsychologia.

[48]  Sterling C. Johnson,et al.  Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation , 2015, Alzheimer's & dementia.

[49]  Irving E. Vega,et al.  Biomarkers for the Early Detection and Progression of Alzheimer’s Disease , 2016, Neurotherapeutics.

[50]  D. Castillo-Carranza,et al.  Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease , 2015, Front. Cell. Neurosci..

[51]  A. Perret‐Liaudet,et al.  Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease , 2015, Front. Neurol..

[52]  Dylan T Burnette,et al.  ER trapping reveals Golgi enzymes continually revisit the ER through a recycling pathway that controls Golgi organization , 2015, Proceedings of the National Academy of Sciences.

[53]  H. Zetterberg,et al.  Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia , 2015, Alzheimer's & dementia.

[54]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[55]  R. Grassi‐Oliveira,et al.  Brazilian preliminary norms and investigation of age and education effects on the Modified Wisconsin Card Sorting Test, Stroop Color and Word test and Digit Span test in adults , 2015, Dementia & neuropsychologia.

[56]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[57]  Henry Engler,et al.  Fluorodeoxyglucose PET in Neurology and Psychiatry. , 2014, PET clinics.

[58]  Michael W. Weiner,et al.  The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[59]  D. Salmon,et al.  Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. , 2014, Journal of Alzheimer's disease : JAD.

[60]  K. Blennow,et al.  Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid , 2013, Acta Neuropathologica.

[61]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[62]  E. Teng,et al.  Clinicopathologic differences among patients with behavioral variant frontotemporal dementia , 2013, Neurology.

[63]  M. Yassuda,et al.  Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment , 2013, International journal of geriatric psychiatry.

[64]  L. Nyberg,et al.  Genetic and Lifestyle Predictors of 15‐Year Longitudinal Change in Episodic Memory , 2012, Journal of the American Geriatrics Society.

[65]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[66]  Mike P. Wattjes,et al.  Visual assessment of posterior atrophy development of a MRI rating scale , 2011, European Radiology.

[67]  M. Brundel,et al.  Cerebral microinfarcts: A systematic review of neuropathological studies , 2011, Alzheimer's & Dementia.

[68]  Ricardo Nitrini,et al.  Criteria for the diagnosis of Alzheimer’s disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology , 2011, Dementia & neuropsychologia.

[69]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[70]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[71]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[72]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[73]  C. Buchpiguel,et al.  Diagnosis of Alzheimer’s disease in Brazil: Supplementary exams , 2011, Dementia & neuropsychologia.

[74]  Howard J. Rosen,et al.  Neuroimaging in Dementia , 2011, Neurotherapeutics.

[75]  J T O'Brien,et al.  EFNS guidelines for the diagnosis and management of Alzheimer’s disease , 2010, European journal of neurology.

[76]  M. Yassuda,et al.  Can the CAMCOG be a good cognitive test for patients with Alzheimer's disease with low levels of education? , 2010, International Psychogeriatrics.

[77]  R. Nitrini,et al.  Functional Disability in Alzheimer Disease: A Validation Study of the Brazilian Version of the Disability Assessment for Dementia (DAD-Br) , 2010, Alzheimer disease and associated disorders.

[78]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[79]  M. Yassuda,et al.  Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults. , 2010, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[80]  M. P. Foss,et al.  REY COMPLEX FIGURES FOR THE ELDERLY , 2010 .

[81]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[82]  Henry Brodaty,et al.  Management of behavioral problems in Alzheimer's disease , 2010, International Psychogeriatrics.

[83]  W. M. van der Flier,et al.  Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. , 2009, Radiology.

[84]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[85]  R. Lourenço,et al.  [Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): cross-cultural adaptation for use in Brazil]. , 2009, Cadernos de saude publica.

[86]  D. Delis,et al.  Quantification of five neuropsychological approaches to defining mild cognitive impairment. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[87]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[88]  M. Yassuda,et al.  CAMcog as a screening tool for diagnosis of mild cognitive impairment and dementia in a Brazilian clinical sample of moderate to high education , 2008, International journal of geriatric psychiatry.

[89]  Sid E O'Bryant,et al.  Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.

[90]  O. Forlenza,et al.  Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[91]  L. Camacho,et al.  [Cross-cultural adaptation of the Independence in Activities of Daily Living Index (Katz Index)]. , 2008, Cadernos de saude publica.

[92]  Julie S. Snowden,et al.  Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk , 2007, Cortex.

[93]  C. Bottino,et al.  The Bayer: Activities of Daily Living Scale (B-ADL) in the differentiation between mild to moderate dementia and normal aging. , 2007, Revista brasileira de psiquiatria.

[94]  L. Malloy-Diniz,et al.  The Rey Auditory-Verbal Learning Test: applicability for the Brazilian elderly population. , 2007, Revista brasileira de psiquiatria.

[95]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[96]  J. Kaye,et al.  Validity of the Clinical Dementia Rating Scale for the Detection and Staging of Dementia in Brazilian Patients , 2007, Alzheimer disease and associated disorders.

[97]  P. Caramelli,et al.  Brazilian adaptation of the Addenbrooke’s Cognitive Examination-Revised (ACE-R) , 2007, Dementia & neuropsychologia.

[98]  Ricardo Nitrini,et al.  Category Fluency as a Screening Test for Alzheimer Disease in Illiterate and Literate Patients , 2007, Alzheimer disease and associated disorders.

[99]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[100]  C. Bottino,et al.  Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[101]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[102]  L. Mansur,et al.  [Boston Naming Test: performance of Brazilian population from São Paulo]. , 2006, Pro-fono : revista de atualizacao cientifica.

[103]  W. M. van der Flier,et al.  Epidemiology and risk factors of dementia , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[104]  B. Damasceno,et al.  [Diagnosis of Alzheimer's disease in Brazil: cognitive and functional evaluation. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology]. , 2005, Arquivos de neuro-psiquiatria.

[105]  J P Miller,et al.  The AD8 , 2005, Neurology.

[106]  A. Damasceno,et al.  [Validation of the Brazilian version of mini-test CASI-S]. , 2005, Arquivos de neuro-psiquiatria.

[107]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[108]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[109]  S. Weintraub,et al.  The Activities of Daily Living Questionnaire: A Validation Study in Patients with Dementia , 2004, Alzheimer disease and associated disorders.

[110]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[111]  Ricardo Nitrini,et al.  Brazilian version of the Mattis dementia rating scale: diagnosis of mild dementia in Alzheimer's disease. , 2003, Arquivos de neuro-psiquiatria.

[112]  K. Shulman,et al.  A population based study on the intra and inter‐rater reliability of the clock drawing test in Brazil: the Bambuí Health and Ageing Study , 2003, International journal of geriatric psychiatry.

[113]  Ricardo Nitrini,et al.  [Suggestions for utilization of the mini-mental state examination in Brazil]. , 2003, Arquivos de neuro-psiquiatria.

[114]  R. Nitrini,et al.  Epidemiologic Survey of Dementia in a Community-Dwelling Brazilian Population , 2002, Alzheimer disease and associated disorders.

[115]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[116]  P. Bertolucci,et al.  The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[117]  P. Bertolucci,et al.  Applicability of the CERAD neuropsychological battery to Brazilian elderly. , 2001, Arquivos de neuro-psiquiatria.

[118]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[119]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[120]  Michael E. Phelps,et al.  Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[121]  H. Lehfeld,et al.  The Bayer Activities of Daily Living Scale (B-ADL) , 1998, Dementia and Geriatric Cognitive Disorders.

[122]  M. Barón,et al.  The Alzheimer's disease assessment scale , 1998, Neurology.

[123]  E. Massad,et al.  [Neuropsychological tests of simple application for diagnosing dementia]. , 1994, Arquivos de neuro-psiquiatria.

[124]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[125]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[126]  Anthony F Jorm,et al.  The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms , 1989, Psychological Medicine.

[127]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[128]  F. Huppert,et al.  CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia , 1986, British Journal of Psychiatry.

[129]  Ivan Silver,et al.  The challenge of time: Clock‐drawing and cognitive function in the elderly , 1986 .

[130]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[131]  M. Albert,et al.  The clinical utility of the dementia rating scale for assessing Alzheimer patients. , 1984, Journal of chronic diseases.

[132]  E. Kaplan,et al.  The Boston naming test , 2001 .

[133]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[134]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[135]  T. Kurosaki,et al.  Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.

[136]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[137]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[138]  イヴォン ブレース,et al.  Presses Universitaires de France刊行の近著解題 , 1952 .

[139]  P. Osterrieth,et al.  Le test de copie d'une figure complexe; contribution à l'étude de la perception et de la mémoire. , 1944 .